Graphical Abstract Highlights d Imidazole propionate levels are increased in subjects with type 2 diabetes (T2D) d Imidazole propionate is produced from histidine by T2Dassociated bacteria d Imidazole propionate impairs glucose tolerance and insulin signaling d Imidazole propionate inhibits IRS via activation of p38g/p62/ mTORC1
INTRODUCTION
Metabolic disorders such as obesity, diabetes, and cardiovascular disease are associated with altered gut microbiota structure and function (Cotillard et al., 2013; Karlsson et al., 2013; Le Chatelier et al., 2013; Qin et al., 2012; Wang et al., 2011) , and recent data suggest that the microbiota contributes to variations in metabolic responses to a given diet (Cotillard et al., 2013; Smith et al., 2013; Sonnenburg and Bä ckhed, 2016) . Studies assessing the effect of diet interventions on the microbiota have mostly focused on dietary fibers, which are precursors for bacterial fermentation, resulting in metabolites (short-chain fatty acids) that are associated with improved metabolism (Koh et al., 2016) . However, recent studies have identified trimethylamine N-oxide (TMAO) as a microbiota-dependent metabolite that contributes to atherosclerosis in mouse models and associates with cardiovascular disease in humans (Koeth et al., 2013; Wang et al., 2011) . In addition, branched-chain amino acids (BCAAs) (Pedersen et al., 2016; Ridaura et al., 2013; Shoaie et al., 2015) , glutamate (Liu et al., 2017) , and amino acid-derived uremic toxins (Aronov et al., 2011; Kikuchi et al., 2017) have been proposed as potentially harmful microbially modulated metabolites. Of note, a recent study identified a gut bacterial pathway that can metabolize aromatic amino acids into bioactive compounds (Dodd et al., 2017) . However, there is little mechanistic insight into how amino acid-derived metabolites contribute to disease.
Here, we identify imidazole propionate as a microbially produced amino acid-derived metabolite that is present at higher concentrations in the portal and peripheral blood of subjects with type 2 diabetes. In addition, we identify bacteria that can produce imidazole propionate from urocanate. Furthermore, we show that imidazole propionate can worsen glucose tolerance when administered to mice and impairs insulin signaling at the level of insulin receptor substrate (IRS). Finally, we characterize the underlying signaling pathways.
RESULTS
Imidazole Propionate Is Associated with Type 2 Diabetes in Humans Bacterial metabolites produced in the gut reach the liver through the portal vein and then enter the systemic circulation. To identify amino acid-derived microbial metabolites that may contribute to insulin resistance and type 2 diabetes, we first performed untargeted metabolomics on plasma obtained from portal blood of 5 obese subjects (body mass index [BMI] > 40) with type 2 diabetes and 10 BMI-matched subjects without type 2 diabetes (Table S1 ). Only four amino acid-derived metabolites (dopamine sulfate, glutamate, imidazole propionate, and N-acetylputrescine) were significantly higher [false discovery rate (FDR) < 0.1] in the portal plasma of subjects with type 2 diabetes (ImP) and glutamate in portal and vena cava plasma of GF and CONVR mice (n = 6 per group). (B) Portal and peripheral plasma levels of ImP in obese BMI-matched subjects without type 2 diabetes (no T2D, n = 10) or with T2D (n = 5). (C) Peripheral plasma levels of ImP or urocanate in humans with normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and treatment-naive T2D.
(D) Histidine utilization pathway. Data presented as boxplots show minimum, 25% quartile, median, 75% quartile, maximum, and mean (marked as +). *p < 0.05, ***p < 0.001; ns, not significant. p values were determined by two-way ANOVA with repeated-measurements (A and B), Kruskal-Wallis test followed by Dunnett's test (C) . See also Figure S1 and Tables S1-S3.
( Table S2 ). To focus on microbial metabolites only, we then investigated levels of these four metabolites in the global metabolomics profile of plasma from C57BL/ 6J germ-free (GF) and conventionally raised (CONVR) mice. We showed that imidazole propionate but not glutamate was present at higher levels both in the portal vein and vena cava plasma from the CONVR mice ( Figure 1A) ; dopamine sulfate and N-acetylputrescine were not detected. We next developed a targeted method for imidazole propionate measurements and verified that the peak in the mice plasma has the same retention time and fragmentation pattern as those of a synthetic reference substance (Figure S1A) . Using this analytical protocol, we also showed that antibiotic treatment of the CONVR mice reduced circulating imidazole propionate levels without significantly affecting body weight (Figures S1B and S1C) , confirming the role of the microbiota in production of imidazole propionate. Targeted measurements of imidazole propionate in plasma obtained from portal and peripheral blood from the initial human cohort: (1) confirmed that concentrations of imidazole propionate were higher in the portal plasma of subjects with type 2 diabetes, and (2) showed that concentrations of imidazole propionate were also higher in the peripheral plasma of subjects with type 2 diabetes compared with those without type 2 diabetes ( Figure 1B) .
To validate our observation of increased concentrations of imidazole propionate in the peripheral blood of those with type 2 diabetes, we recruited 649 middle-aged individuals from the Swedish population and divided them into four groups according to their level of glucose tolerance (Table S3 ). We observed significantly higher levels of imidazole propionate across the groups (p < 0.0001) and those with treatment-naive type 2 diabetes had higher levels of imidazole propionate compared with those with normal glucose tolerance after correcting for the potential confounding factors BMI, sex, and age (p < 0.0001) ( Figure 1C ). By contrast, the levels of its precursor, urocanate ( Figure 1D ), did not differ between the groups ( Figure 1C ).
To directly address if imidazole propionate is a microbially produced metabolite, we monitored the kinetics of imidazole propionate production in an in vitro gut simulator (a continuously fed stabilized microbial community maintained in an anaerobic, reducing environment mimicking that of the gut). After 1 week stabilization of the microbial communities from obese subjects with or without type 2 diabetes from the first cohort (n = 2 per group), we challenged the communities with 10 mM histidine and measured the levels of imidazole propionate for 7 hr. The bacterial communities from subjects without type 2 diabetes barely produced imidazole propionate at any time point whereas the bacterial communities from subjects with type 2 diabetes produced imidazole propionate after 1.5 hr and continued to produce imidazole propionate at the 7 hr time point (Figure 2A ). To validate these findings, we performed batch culture and compared imidazole propionate production from histidine in bacterial communities from subjects with and without type 2 diabetes (n = 5 per group from the first cohort and n = 3 per group from the second cohort). End-point measurements showed that higher concentrations of imidazole propionate were produced in the presence of the type 2 diabetes-associated microbiota (Figures 2B and 2C) . These observations suggest that type 2 diabetes-associated microbiota shunts urocanate to a lesserknown pathway to produce imidazole propionate ( Figure 1D ).
To identify bacteria that can produce imidazole propionate from urocanate, we performed large-scale screening for potential urocanate reductases (UrdAs) based on FAD-binding domains in the active sites ( Figure S2A ). We identified 812 UrdA homologs in bacterial genomes: 639 with conserved ''H'' and 173 without ''H'' (replaced with ''Y'' or ''M'') ( Figure S2B ; Table S4 ). We showed that bacteria with ''Y''-or ''M''-UrdA homologs but not those with ''H''-UrdA homologs produced imidazole propionate from urocanate ( Figure 2D ); thus bacteria with ''Y''-or ''M''-UrdA homologs are authentic UrdA. Using a previously published metagenomics dataset that included subjects with treatment-naive type 2 diabetes and subjects with normal glucose tolerance (Karlsson et al., 2013) , we identified 42 bacterial strains with authentic UrdA, 28 (67%) of which were more abundant in subjects with type 2 diabetes ( Figure 2E ). We noted, for example, that Streptococcus mutans and Eggerthella lenta (at the strain level), which we verified as imidazole propionate producers in vitro ( Figure 2D ), were more abundant in subjects with type 2 diabetes ( Figure 2E ), supporting an association between imidazole propionate production and the pathogenesis of type 2 diabetes.
Imidazole Propionate Impairs Glucose Tolerance and Insulin Signaling
To directly test whether imidazole propionate could affect glucose metabolism, we injected vehicle or imidazole propionate intraperitoneally into GF mice for 3 days. We observed that this treatment increased circulating concentrations of imidazole propionate from 1.4 nM to around 13 nM without affecting urocanate concentrations ( Figure 3A ) and increased imidazole propionate levels in the liver ( Figure S3A ). The presence of low concentrations of imidazole propionate in vehicle-injected GF mice is likely explained by the fact that the chow diet fed to the mice contained imidazole propionate ( Figure S3B ). Importantly, glucose intolerance was induced in imidazole propionate-injected GF mice ( Figure 3B ), supporting a role for imidazole propionate as a plausible contributor to impaired glucose metabolism in vivo. However, insulin levels were not affected by imidazole propionate ( Figure S3C ). We also observed that hepatic expression of G6pase and Pepck, genes for key rate-limiting gluconeogenic enzymes, was significantly increased in imidazole propionate-injected GF mice compared with controls ( Figure 3C ). However, imidazole propionate did not affect hepatic expression of Srebp1c and Fasn, key lipogenic genes ( Figure 3C ).
We also showed that 3-day injections of imidazole propionate in CONVR mice increased concentrations of imidazole propionate in the circulation and in the liver (Figures 3D and S3D) . Of note, imidazole propionate treatment impaired glucose tolerance ( Figure 3E ) without any significant effect on body weight, liver and white adipose tissue (WAT) weight, food intake, or insulin levels ( Figures S3E-S3H ). Energy expenditure in the early dark phase was significantly reduced by imidazole propionate; however, total locomotor activity was not significantly reduced by imidazole propionate treatment ( Figures S3I-S3K ). By implanting slow-releasing pellets containing either placebo or imidazole propionate in CONVR mice, we showed that long-term treatment (14 days) with imidazole propionate caused significant impairment of glucose tolerance ( Figure 3F ) without affecting body weight, liver and WAT weight, or insulin levels (Figures S3L-S3O).
We next investigated the effect of imidazole propionate injections on key proteins involved in insulin signaling in mice. We found that 3-day injections of imidazole propionate in GF mice did not affect hepatic levels of the insulin receptor (IR) or basal Akt phosphorylation (S473) but reduced hepatic levels of IRS1 and IRS2 ( Figure 3G ). These reductions occurred post-transcriptionally because there were no significant changes in hepatic Irs1 and Irs2 mRNA levels ( Figure S3P ). We also showed a reduction of IRS2 (but not IRS1) in muscle ( Figure 3H ) and of IRS1 (but not IRS2) in WAT ( Figure 3I ). Imidazole propionate treatment for 3 days did not affect IRS protein levels in CONVR mice (Figure S3Q) . However, 14-day treatment with imidazole propionate reduced IRS2 levels in liver and muscle of CONVR mice without reducing IRS1 levels; a trend toward a reduction in IRS1 was observed in WAT, but IRS2 was not detected ( Figure S3R ). Previous reports have shown that insulin has different effects on IRS1 or IRS2 reduction depending on the cell type and even on the differentiation status of the same cell type (Rui et al., 2001) .
To further investigate the role of imidazole propionate on insulin signaling, we used primary hepatocytes. Incubation with imidazole propionate for 8 hr did not affect IRS1 levels but significantly blunted insulin-induced IRS1 Y612 phosphorylation ( Figure 3J ), which is required for insulin-stimulated activation of IRS1-associated phosphatidylinositol-3 kinase and downstream (A) Production of imidazole propionate (ImP) from 10 mM histidine in an in vitro gut simulator inoculated (in separate experiments) with feces from two subjects without type 2 diabetes (T2D) or from two subjects with T2D. (B) End-point measurements of ImP production from 10 mM histidine in batch culture experiments using feces from obese BMI-matched subjects without T2D (n = 5) or with T2D (n = 5).
Akt (Esposito et al., 2001) . In addition, we showed that 20 hr incubation of hepatocytes with imidazole propionate reduced IRS1 and IRS2 levels ( Figure 3K ) and significantly inhibited insulin-stimulated Akt phosphorylation ( Figure 3L ). We also noted that IRS1 levels were reduced by 8 hr treatment of imidazole propionate in the human embryonic kidney cell line HEK293 ( Figure 3M ), indicating that imidazole propionate acts through a pathway that is conserved across cell types (although its effect was more rapidly induced in HEK293 cells than in primary hepatocytes). In addition, we showed that the imidazole propionate-induced reduction in IRS levels in HEK293 cells was inhibited by the proteasome inhibitor MG132 ( Figure 3M ), suggesting the involvement of a proteasome-dependent pathway.
Together, these data show that imidazole propionate has negative impacts on insulin signaling at the level of IRS (i.e., inhibiting tyrosine phosphorylation or reducing protein levels).
Imidazole Propionate Activates mTORC1
We speculated that imidazole propionate inhibits insulin signaling through mTORC1, which is known to induce IRS serine phosphorylation leading to inhibition of IRS tyrosine phosphorylation and/or proteasomal degradation of IRS (Harrington et al., 2004; Leontieva et al., 2014; Ozes et al., 2001) . In agreement with our hypothesis, we showed that: (1) imidazole propionate as well as leucine, a well-known mTORC1 activator, increased phosphorylation of S6K1 (a marker of mTORC1 activation) in primary hepatocytes; and (2) rapamycin and torin 1 (inhibitors of mTORC1 and mTORC1/2, respectively) inhibited the imidazole propionate-induced increase in S6K1 phosphorylation and reduction in IRS levels (Figures 4A, S4A, and S4B) .
In HEK293 cells, mTORC1 depletion by Raptor knockdown prevented imidazole propionate-mediated induction of IRS1 S636/S639 phosphorylation and inhibition of insulin-stimulated IRS1 tyrosine phosphorylation; however, this treatment did not completely reverse imidazole propionate-induced S6K1 phosphorylation or prevent imidazole propionate-induced IRS1 reduction, possibly due to incomplete knockdown of Raptor ( Figure 4B ). mTORC1 can only induce S636/S639 phosphorylation of IRS1 in vitro; however, S6K1 induces serine phosphorylation on multiple sites of IRS1 in vivo, which is required for IRS1 degradation (Harrington et al., 2004; Leontieva et al., 2014; Ozes et al., 2001; Shah and Hunter, 2006; Tzatsos, 2009) . We showed that S6K1 knockdown in HEK293 cells inhibited imidazole propionateinduced induction of IRS1 S636/S639 phosphorylation, inhibition of insulin-stimulated IRS1 tyrosine phosphorylation, and reduction of IRS1 levels ( Figure 4B ). Because IRS serine phosphoryla-tion is known to precede IRS degradation (Harrington et al., 2004; Leontieva et al., 2014; Ozes et al., 2001) , we suggest that imidazole propionate can have impacts on both IRS1 serine phosphorylation and subsequent degradation. Furthermore, S6K1 knockdown promoted hypersensitivity to insulin as observed by higher insulin-induced phosphorylation of Akt in the presence of imidazole propionate, which likely caused activation of the S6K1 remaining after incomplete knockdown ( Figure 4B ).
Consistent with our hypothesis that imidazole propionate signals through mTORC1, we observed that 3-day imidazole propionate treatment in vivo increased S6K1 phosphorylation in the liver, soleus muscle, and WAT of CONVR mice ( Figure 4C ). This treatment also increased S6K1 phosphorylation in the liver of GF mice without affecting mTOR S2481 autophosphorylation or autophagy ( Figure 4D ). In addition, we showed that imidazole propionate promoted a time-dependent increase in S6K1 phosphorylation in HEK293 cells ( Figure 4E ).
In contrast to insulin, which induces mTOR S2481 autophosphorylation but cannot activate mTORC1 in the absence of amino acids (Soliman et al., 2010; Wang et al., 2005) , imidazole propionate did not promote mTOR S2481 autophosphorylation in HEK293 cells ( Figure 4E ) but induced S6K1 phosphorylation in amino acid-deprived primary hepatocytes ( Figure 4F ). We also showed that 1 hr incubation with imidazole propionate in amino acid-deprived HEK293 cells induced S6K1 phosphorylation to a similar extent as that induced by amino acid stimulation for 1 hr ( Figure S4C ). Moreover, in amino acid-deprived HEK293 cells, imidazole propionate induced phosphorylation of S2448 but not S2481 of mTORC1 ( Figure 4G ). This is consistent with previous results showing that mTORC1 activity associates with phosphorylation of S2448 but not S2481 of mTORC1 (Copp et al., 2009) .
Earlier studies have shown that amino acid-induced mTORC1 activation requires mTORC1 localization to the lysosome, which is mediated by the formation of a complex between the active Rag heterodimer RagA/B-GTP/RagC/D-GDP and mTORC1 (Raptor and mTOR) (Duran et al., 2011; Sancak et al., 2008) . We showed that imidazole propionate also induced lysosomal localization of mTOR in amino acid-deprived HEK293 cells (Figure 4H) and that RagA/B-GDP and RagC/D-GTP, which are inactive Rag GTPases, blocked the imidazole propionate-induced S6K1 phosphorylation ( Figure S4D ). Moreover, the active Rag GTPases RagA/B-GTP did not further increase S6K1 phosphorylation ( Figure S4D ). By performing immunoprecipitation with FLAG-tagged mTOR and monitoring interaction with HA-tagged Raptor and Myc-tagged Rag GTPases, we showed that imidazole propionate induced formation of the mTORC1-Rag heterodimer ( Figure S4E ). In addition, we observed that imidazole (C) End-point measurements of ImP production from 10 mM histidine in batch culture experiments using feces from subjects with normal glucose tolerance (NGT) (n = 3) or with treatment-naive T2D (n = 3). (D) Prediction of ImP-producing bacteria and experimental validation using histidine or urocanate as substrate. ImP production shown as log transformed foldchange compared with blank samples. (E) Abundance of bacteria with ''non-H''-UrdA in subjects with treatment-naive T2D (n = 33) or with NGT (n = 43) from a previously published metagenomic dataset (Karlsson et al., 2013) . Bacterial strains that were significantly higher or lower in subjects with T2D compared with subjects with NGT are shown as red or blue bars, respectively (cut-off 100 reads; FDR < 0.05). Data presented as boxplots show minimum, 25% quartile, median, 75% quartile, maximum, and mean (marked as +). *p < 0.05. p values were determined by Wilcoxon one-tailed test (B and C) . See also Figure S2 and Table S4 . (legend continued on next page) propionate could promote mTORC1/RagB complex formation in the presence of amino acids ( Figure S4F ), indicating that imidazole propionate can act as an mTORC1 activator in (patho) physiological conditions in vivo (i.e., in the presence of amino acids).
Imidazole Propionate-Induced mTORC1 Activation Is Dependent on p62 Phosphorylation Phosphorylation of the adaptor protein p62 at T269 and S272 has recently been shown to be critical for amino acid induction of mTORC1 activation (Linares et al., 2015) . Here, we showed that imidazole propionate induced p62 phosphorylation in liver and primary hepatocytes from CONVR mice (Figures 5A and 5B) . In primary hepatocytes, this response was not affected by rapamycin or torin 1 ( Figure 5B ), indicating that mTORC1 is downstream of p62 phosphorylation. Imidazole propionate promoted a concentration-dependent increase in p62 phosphorylation in HEK293 cells, with activation observed at concentrations as low as 10 nM in the absence of amino acids ( Figure S5A ). Compared with p62, S6K1 and IRS1 S636/S639 were less sensitive to imidazole propionate ( Figure S5A ), again supporting a role for p62 phosphorylation upstream of mTORC1. Furthermore, p62 knockdown by small interfering RNA (siRNA) reduced imidazole propionate-induced S6K1 and IRS1 S636/S639 phosphorylation ( Figure 5C ). Together these data suggest that p62 is a mediator of imidazole propionate-induced mTORC1 activation. Of note, neither p62 nor S6K1 was phosphorylated by histidine, its metabolites urocanate and glutamate, or the structurally similar bacterial metabolite indole propionate ( Figure 5D ), highlighting the specificity of imidazole propionate. We next determined if the p62 phosphorylation-deficient mutant T269A/S272A could block imidazole propionate-induced signaling in HEK293 cells. We first showed that this protein is a dominant-negative mutant as it reduced imidazole propionateinduced p62 phosphorylation (Figures 5E and 5F) . Both in the absence and presence of amino acids, expression of p62 T269A/S272A: (1) inhibited imidazole propionate-induced phosphorylation of S6K1 and IRS1 (S636/S639) (Figures 5E and 5F); and (2) disrupted imidazole propionate-induced complex formation between mTORC1 and RagB ( Figures S5B and S5C ). Although the detailed mechanism of action needs to be investigated further, these data indicate that p62 phosphorylation at T269/S272 promotes transmission of the imidazole propionate signal to mTORC1.
Alternative p38 Promotes Imidazole Propionate-Induced p62 and mTORC1 Activation There are four p38 mitogen-activated protein kinase (MAPK) isoforms in mammalian cells, which can be divided into two subsets depending on their substrate specificity: p38a/p38b and p38g/ p38d (also called alternative p38 MAPK) (Cuenda and Rousseau, 2007) . A recent study reported that p38d, but not p38a/p38b nor p38g, is required to mediate the amino acid-induced activation of p62 and mTORC1 in HEK293 cells (Linares et al., 2015) .
Here, we showed that knockdown of p38a or p38b in HEK293 cells did not affect p62 and mTORC1 activation ( Figure 6A ). Although knockdown of p38d partly inhibited imidazole propionate-induced phosphorylation of p62 and S6K1, it did not affect IRS1 ( Figures 6B and S6A ). By contrast, p38g knockdown blocked imidazole propionate-induced phosphorylation of p62, S6K1, and IRS1 S636/S639 in amino acid-deprived HEK293 cells ( Figures 6B and S6B ). Furthermore, we showed that p38g but not p38d was expressed in primary hepatocytes whereas HEK293 cells express both isoforms ( Figure S6C ); despite this difference, imidazole propionate had similar effects on p62 phosphorylation in both cell types ( Figures 5B and 5D ). Thus, although we cannot exclude a role for p38d in imidazole propionate-induced mTORC1 signaling in some cell types, our data show that p38g potentially plays a greater role in mediating the signal from imidazole propionate to activation of p62 and mTORC1. Of note, we also showed that p38g knockdown inhibited IRS reduction induced by 8 hr incubation with imidazole propionate in HEK293 cells in the presence of amino acids ( Figure 6C ).
By performing an in vitro kinase assay, we showed that p62 phosphorylation (at T269 and S272) was induced by p38g in the presence of 50 mM ATP, which was further increased with 200 mM ATP ( Figure 6D ), identifying p38g as a direct kinase for p62 phosphorylation. Importantly, imidazole propionate enhanced p62 phosphorylation in a concentration-dependent manner ( Figure 6D ), indicating that imidazole propionate could directly promote p38g activity in vitro. The activation of p38 MAPKs including p38g is known to be mediated by phosphorylation at T180/Y182 by upstream kinases. ATP itself did not induce p38g autophosphorylation; however, imidazole propionate together with ATP induced p38g autophosphorylation. Although upstream kinase-mediated p38 phosphorylation is the conventional mechanism to activate p38, there are studies that support p38 autophosphorylation and thus suggest that p38 can activate itself (Ashwell, 2006; Beenstock et al., 2014; Ge et al., 2002; Kim et al., 2005) .
Imidazole Propionate Associates with p62 and S6K1 Phosphorylation in Human Liver
Consistent with our initial observation that imidazole propionate concentrations were higher in individuals with versus those without type 2 diabetes ( Figure 1B ), we showed that phosphorylation of p62 and S6K1 was higher in liver from subjects with (K) Effect of long-term ImP treatment (100 mM for 20 hr) on IRS protein levels in primary hepatocytes (n = 7). (L) Effect of ImP or the tyrosine-derived microbial metabolite phenol sulfate (PS) (both 100 mM for 20 hr) on Akt activation simulated by insulin (5 nM) in primary hepatocytes (n = 4). (M) Effect of the proteasome inhibitor MG132 on IRS reduction induced by ImP (100 mM) in serum-starved HEK293 cells (n = 3); cells were co-treated with MG132 and ImP for 8 hr. TX, triton. Data in (A) and (D) are presented as boxplots and show minimum, 25% quartile, median, 75% quartile, and maximum. Other data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Two-way ANOVA with repeated-measurements followed by Sidak multiple comparisons test (A and D) and unpaired two-tailed Student's t tests (B-L). One-way ANOVA followed by Tukey's multiple comparisons test (M). See also Figure S3 . (legend continued on next page) type 2 diabetes than in those without type 2 diabetes (n = 5 and 7, respectively, from the initial cohort) ( Figure 7A ). We did not observe any difference in hepatic IRS1 levels between those with and without type 2 diabetes, but IRS2 levels were significantly lower in subjects with type 2 diabetes ( Figure 7A ). Although mTORC1 activation is known to promote the degradation of both IRS1 and IRS2, either IRS1 or IRS2 can be targeted for proteasomal degradation depending on the cell type (Rui et al., 2001) . We did not observe any differences in mTOR S2481 phosphorylation (i.e., autophosphorylation) or in phosphorylation of AMPK T172 and Akt S473, two known upstream regulators of mTORC1 (Yang and Guan, 2007) ( Figure 7A ). Furthermore, correlation analysis showed that: (1) plasma HbA1c positively associated with phosphorylation of p62 and S6K1 but not with phosphorylation of AMPK and Akt;
(2) plasma HbA1c negatively associated with IRS2 in the liver; (3) there was a positive correlation between p62 and S6K1 phosphorylation; and (4) portal levels of imidazole propionate positively correlated with p62 and S6K1 phosphorylation ( Figures 7B and 7C ). These data are consistent with a role for imidazole propionate in impairing insulin signaling through the p62 and mTORC1 pathway.
Previous studies have shown that BCAAs are associated with insulin resistance (Pedersen et al., 2016) and that they activate p62 and mTORC1 (Linares et al., 2015) . However, although we showed that portal levels of imidazole propionate from these subjects positively correlated with phosphorylation of p62 and S6K1, we did not observe any significant correlations between BCAAs and phosphorylation of p62 and S6K1 ( Figure 7C ).
DISCUSSION
We have identified imidazole propionate as a microbially produced histidine-derived metabolite that is increased in subjects with type 2 diabetes. We also identified bacteria that could produce imidazole propionate and showed that imidazole propionate treatment impairs glucose tolerance in mice. We further showed that imidazole propionate inhibits insulin signaling at the level of IRS through activation of the p38g/p62/mTORC1 pathway at the cellular level ( Figure 7D ). Finally, consistent with a potential role for imidazole propionate in impairment of insulin signaling in humans, we showed increased activation of p62 and mTORC1 in liver from subjects with type 2 diabetes.
An earlier study reported that imidazole propionate is excreted from patients with intestinal disorders but is almost absent in feces and urine from healthy subjects (van der Heiden et al., 1972) , supporting the concept of imidazole propionate as a microbial metabolite with detrimental health effects. Our results showing that imidazole propionate is not only present at higher concentrations in subjects with type 2 diabetes but is present at similar concentrations in the portal and peripheral blood indicate that this metabolite could have systemic effects.
To modify the production of microbial metabolites, it is important to identify the metabolic pathways required for their production. Histidine degradation pathways leading to the production of urocanate and glutamate are well conserved both in bacteria and humans (Bender, 2012) . However, the bacterial UrdA, which catalyzes the production of imidazole propionate from urocanate, has only recently been discovered (in Shewanella oneidensis) (Bogachev et al., 2012) . A major hurdle to identifying UrdAs is their high sequence homology with fumarate reductase and succinate dehydrogenase. Here, we showed that bacteria with ''Y'' or ''M''-UrdA homologs (without ''H'') are authentic UrdAs and further showed increased abundance of strains with the capability of producing imidazole propionate in subjects with type 2 diabetes. We speculate that a shift in the gut environment resulting from dietary changes and/or an altered immune system (Schroeder and Bä ckhed, 2016) can contribute to the expansion of imidazole propionate-producing bacteria. Because urocanate can be used as an electron acceptor in UrdA-containing bacteria, depletion of other common electron acceptors such as fumarate, ferric ion, and nitrate may confer a growth benefit to these bacteria (Bogachev et al., 2012) . In addition, because UrdA is active at neutral pH (Bogachev et al., 2012) and the proximal colon has an acidic pH, increases in pH, possibly resulting from decreased production of short-chain fatty acids and increased protein fermentation in the gut (Windey et al., 2012) , may increase production of imidazole propionate. Accordingly, clarification of the interplay between diets, bacteria, and the gut environment would be important to understand how to modify imidazole propionate production in humans.
In this study, we demonstrated the signaling potential of imidazole propionate by identifying alternative p38 MAPK as a target of imidazole propionate. Alternative p38 MAPK has a broad spectrum of tissue expression (Beardmore et al., 2005) , and both p38g and p38d are implicated in pathological conditions including impaired glucose tolerance (Gonzá lez-Terá n et al., 2016). Moreover, because imidazole propionate induced sustained activation of mTORC1, it is thus potentially linked to pathological conditions related to mTORC1 hyperactivation not only in diabetic complications (retinopathy, nephropathy, and heart failure) but also in cancer (Blagosklonny, 2013) .
Although BCAAs have been suggested to link hyperactivation of mTORC1 with insulin resistance, several studies have demonstrated that dietary supplementation with BCAAs improves metabolic health (Chen and Reimer, 2009; Layman and Walker, 2006; Mojtahedi et al., 2011; Muto et al., 2006; Qin et al., 2011;  (F) Rapid effects of ImP (100 mM) on pS6K1 in amino acid-deprived primary hepatocytes (n = 3). (G) Effects of ImP or amino acids (a.a) on mTORC1-associated mTOR phosphorylation. HEK293 cells transfected with Flag mTOR and HA Raptor were serumand amino acid-deprived, stimulated with ImP or a.a for 2 hr and subjected to mTORC1 immunoprecipitation with HA Raptor (n = 3 for control and ImP and n = 2 for a.a). (H) Images of amino acid-deprived HEK293 cells incubated with ImP (100 mM for 1 hr) and co-immunostained for mTOR and LAMP2, showing lysosomal localization of mTOR. Scale bar, 10 mm. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant. One-way ANOVA followed by Tukey's test (A and G), one-way ANOVA followed by Dunnett's test (B) , and unpaired two-tailed Student's t tests (C, D, and F) . See also Figure S4 . (D) In vitro kinase assay (n = 3). p38g and p62 were preincubated and the kinase reaction was started by adding ATP in the absence or presence of ImP. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant. One-way ANOVA followed by Dunnett's test (A and B) . Unpaired two-tailed Student's t tests (C and D) . See also Figure S6 . Zhang et al., 2007) . It is tempting to speculate that imidazole propionate-induced mTORC1 activation might instead be the link between microbiota, mTORC1 hyperactivation, and human health; future studies that assess the impact on host metabolism of blocking imidazole propionate production in bacteria would test this possibility. Of note, imidazole-based drugs bind to a variety of therapeutic targets (Gaba and Mohan, 2016) , suggesting that other signaling pathways can be triggered by imidazole propionate. Thus, further identification of signaling pathways induced by imidazole propionate may reveal drug targets to tackle human disease associated with altered microbial metabolism.
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Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Fredrik Bä ckhed (fredrik@wlab.gu.se).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human study populations Two human cohorts were used in this study The first cohort comprised 5 obese subjects with type 2 diabetes and 10 BMI-matched subjects without type 2 diabetes who were undergoing laparoscopic Roux-and-Y gastric bypass surgery at the Slotervaart Hospital, Amsterdam, the Netherlands (Table S1 ). All of the subjects with type 2 diabetes were on metformin treatment and two of these were also on insulin treatment. Subjects were fasted overnight before the morning of the surgery, and a peripheral venous sample was taken just before the patient went into the operating room. Anthropometric measurements and a stool sample were also taken before surgery. During the surgery, a portal vein sample (vena puncture) was taken as previously described (Anjani et al., 2015) and liver biopsies were also obtained. Fasting glucose (by glucose meters, Roche Diagnostics), insulin (by an electrochemiluminescence immunoassay, Roche Modular System), and HbA1c (Menarini Diagnostic) were measured in the peripheral blood plasma. All participants gave informed consent before the surgery and the protocol was approved by the Medical Ethical Committee of the Slotervaart Hospital, Amsterdam, the Netherlands. The second cohort comprised 649 subjects from a randomly selected population sample of adults aged 50 to 64 years and living in the Gothenburg area, Sweden. These subjects were recruited from the census register. Exclusion criteria were: known diabetes; inflammatory diseases, such as Crohn 0 s disease, ulcerative colitis, rheumatic diseases; treatment with steroids or immunomodulatory drugs; cancer (unless relapse free for the preceding 5 years); cognitive dysfunction. A 75 g oral glucose tolerance test (OGTT) was performed in the morning after an overnight fast, and fasting-and 2-h post load capillary blood glucose were measured. Subjects fulfilling criteria for type 2 diabetes were re-examined with a repeated OGTT within 3 weeks. Subjects were included in the study if they were found to have impaired fasting glucose (n = 119), impaired glucose tolerance (n = 142), or type 2 diabetes (n = 53). In addition, approximately every fifth subject with normal glucose tolerance was included (n = 335). Blood samples were obtained from all the participants. Examinations took place at the Wallenberg Laboratory, University of Gothenburg, Sweden. All participants gave informed consent and the study was approved by the Ethics Committee at Gothenburg University.
Both men and women were included in both study cohorts. However, due to the relative few individuals in the first cohort we could not perform separate analyses of men and women. In the second cohort we corrected the results for potential confounders such as sex. In agreement, separate analyses of imidazole propionate levels in men and women revealed that the metabolite was elevated in both men (7.6 ± 0.5 nM versus 15.1 ± 1.2 nM; p < 0.001) and women (11.2 ± 0.6 nM versus 24.9 ± 5.8 nM; p < 0.001) with type 2 diabetes compared with controls with normal glucose tolerance.
Mice 10-15-week-old male GF and CONVR C57BL/6J mice were used in the animal experiments. GF mice were maintained in flexible film isolators under a strict 12 h light cycle and all mice had unlimited access to water and food. GF status was routinely tested by culturing fecal bacteria anaerobically and aerobically and also was verified regularly by PCR for bacterial 16S rDNA using the primers 27 F and 1492 R (Key Resources Table) . PCR reactions were performed with a 5-min preincubation at 95 C followed by 30 cycles of 30 s at 94 C, 45 s at 52 C, and 90 s at 72 C and then kept at 72 C for 7 min. All mice were fed an autoclaved chow diet (5021 LabDiet) ad libitum. All mice experiments were performed in our animal facility and were approved by the Ethics Committee on Animal Care and Use in Gothenburg, Sweden.
Bacterial strains
Eight representative UrdA-containing bacterial strains (without conserved ''H,'' Key Resources Table) and control strains Escherichia coli k12 and Bifidobacterium longum NCC2705 (with conserved ''H,'' Key Resources Table) were maintained on brain-heart infusion (BHI) medium as described below without histidine or urocanate under strict anaerobic conditions in a Coy chamber (5% hydrogen, 10% carbon dioxide and 85% nitrogen) at 37 C.
Continued

REAGENT or RESOURCE SOURCE IDENTIFIER
Centrifuge Eppendorf 5430R
Nitrogen evaporator Techne FSC400D
Nitrocellulose membrane (0.45 mm pore) Invitrogen LC2001
Primary hepatocytes
Primary hepatocytes were isolated from male C57BL/6J mice by digesting liver with perfusion of collagenase type IV as described previously (Zhang et al., 2012) . After perfusion, 16 3 10 5 cells were plated on collagen-coated 60 mm dishes in Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with fetal bovine serum (FBS), penicillin/streptomycin, and 100 nM dexamethasone. After 4 h, the medium was changed to DMEM/F12 containing penicillin/streptomycin. For insulin stimulation, primary hepatocytes were cultured in DMEM/F12 with or without 100 mM imidazole propionate for 8 to 20 h and treated with 5 nM insulin for the indicated times. For amino acid deprivation, primary hepatocytes were cultured in DMEM/F12 for 24 h, rinsed once with Earle's Balanced Salt Solution (EBSS) and then incubated in EBSS for 1 h before incubation with 100 mM imidazole propionate for the indicated times.
HEK293 cells
For imidazole propionate stimulation in the absence of amino acids, HEK293 cells (ATCC CRL-1573) grown and maintained in 4.5 g/l glucose DMEM with 10% (v/v) FBS were serum-starved for 18 h and then amino acid-deprived with EBSS for 1 h. Otherwise, HEK293 cells grown in RPMI-HEPES with 10% (v/v) FBS were serum-starved for 18 h. For transfection, HEK293 cells cultured in poly-L-lysinecoated 60 mm dish for 18 h were transfected (with plasmids or siRNA as indicated) for 4 h; after replacing the medium, the cells were cultured for another 24 h and then serum-starved for 18 h. For insulin stimulation, serum-starved HEK293 cells were preincubated with imidazole propionate for 8 h and treated with 5 nM insulin.
METHOD DETAILS
Antibiotic treatment
Antibiotic cocktails in drinking water (containing 100 mg/ml neomycin, 50 mg/ml streptomycin, 100 mg/ml ampicillin, 50 mg/ml vancomycin, 100 mg/ml metronidazole, 1 mg/ml bacitracin, 125 mg/ml ciprofloxacin, and 100 mg/ml ceftazidime) were freshly prepared every two days and were given ad libitum for 10 days to C57BL/6J CONVR mice. This protocol was chosen since it was reported not to promote loss of body weight (Suá rez-Zamorano et al., 2015) .
Acute imidazole propionate injection
To test the effect of imidazole propionate on glucose metabolism, 500 mg imidazole propionate in 200 ml water containing 1% DMSO (18 mM) or vehicle (1% DMSO in water) was injected intraperitoneally into GF C57BL/6J mice twice per day for 3 days. For CONVR mice, 100 mg imidazole propionate in 200 ml vehicle (3.6 mM) was used since CONVR mice are continuously exposed to microbial metabolites and have longer retention time of organic solutes compared with GF mice (Mishima et al., 2017) . At day 4, mice were injected again with either vehicle or imidazole propionate and then fasted for 4 h. Intraperitoneal glucose tolerance test (1 g/kg body weight, Fresenius Kabi) was then performed after fasting. Blood glucose levels were measured from tail blood using glucose meters (Bayer Contour XT) at 0, 15, 30, 60, and 120 min after glucose injection. Blood samples for analysis of insulin were taken in serum clot activator tubes (Microvette â CB 300 Z) before and 15 and 30 min after glucose injection. Serum insulin was measured with Ultra-Sensitive mouse Insulin ELISA kit. Plasma samples to measure the levels of imidazole propionate and urocanate were collected from the portal vein and/or vena cava in EDTA-containing tubes (Micro tube 1.3ml K3E) at the end of experiments. Mice were under isoflurane anesthesia and fresh tissues were taken, snap-frozen in liquid nitrogen and stored at À80 C until protein extraction.
Imidazole propionate pellet implantation
To test the long-term consequence of imidazole propionate treatment, slow-releasing pellets containing either placebo or 4.9 mg imidazole propionate (350 mg/day) were implanted subcutaneously under isoflurane anesthesia in CONVR C57BL/6J mice. Pellets were custom-made (by Innovative Research of America, Sarasota, FL) to release either placebo or imidazole propionate continuously for 14 days. Briefly, a small (5 mm) incision was made at the nape of the neck, the pellet was inserted and the incision closed with sutures. After 14 days, an intraperitoneal glucose tolerance test was performed after 4 h fasting as described above. Tissues were snap frozen in liquid nitrogen and stored at À80 C until protein extraction. Plasma samples were collected as described above.
TSE system
To assess the metabolic impact of imidazole propionate on CONVR C57BL/6J mice, food intake, oxygen consumption and locomotor activity were measured using the PhenoMaster system according to the manufacture's recommendation. Mice were singlehoused for two days before being transferred to the PhenoMaster cages, and allowed an additional two days to acclimatize to the new cage before taking measurements. Parameters were automatically measured every 15 min for five days. During the measurements, the mice had free access to water and food. Mice were randomly divided into two weight-matched groups and injected intraperitoneally either with imidazole propionate (100 mg) or vehicle twice a day (8 AM and 5 PM) for three days. Measurements of oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), and energy expenditure ([3.941(VO 2 ) + 1.106(VCO 2 )]/1000) were adjusted to lean body mass, which was determined by MRI (EchoMRI, Houston, TX).
Metabolite analysis
Global metabolite profiling analysis on (1) plasma from portal blood obtained from obese humans with and without type 2 diabetes and (2) plasma from the portal vein and vena cava of C57BL/6J GF and CONVR mice was performed by Metabolon (Durham, NC) using ultra high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS). In brief, samples were prepared using the automated MicroLab STARâ system (Hamilton Company). A recovery standard was added before the first step in the extraction process for quality control. Proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five fractions: one for analysis by UPLC-MS/MS with positive ion mode electrospray ionization, one for analysis by UPLC-MS/MS with negative ion mode electrospray ionization, one for LC polar platform, one for analysis by GC-MS, and one sample was reserved for backup. Samples were placed briefly on a TurboVapâ (Zymark) to remove the organic solvent. For LC, the samples were stored overnight under nitrogen before preparation for analysis. For GC, each sample was dried under vacuum overnight before preparation for analysis. For targeted measurement of imidazole propionate and urocanate, plasma samples were extracted with 3 volumes of ice-cold acetonitrile in 1.5 ml polypropylene tube. After vortexing and centrifugation, the supernatant was dried under a gentle flow of nitrogen. The samples were then reconstituted with 5% HCl (37%) in 1-butanol at 70 C for 1 h and dried under a nitrogen flow, allowing n-butyl ester to be formed. After derivatization, the samples were evaporated and reconstituted in 100 ml of water/acetonitrile (90:10) containing 50 nM of internal standards (labeled imidazole propionate and urocanate made from derivatization using d 10 -labeled butanol). Samples (5 ml) were injected onto a C18 BEH column (2.1x100 mm with 1.7 mm particles; Waters, Milford, MA) and separated using a gradient consisting of water with 0.1% formic acid (A-phase) and acetonitrile with 0.1% formic acid (B-phase) . Mass spectrometric analysis was performed using an Infinity 1290 quaternary UPLC pump (Agilent, Santa Clara, CA) coupled to a QTRAP 5500 (Sciex, Concord, Canada) . The imidazole propionate and urocanate were detected by multiple reaction monitoring using the transitions 197/81 and 195/93, respectively. For the internal standards, the transitions 206/81 and 204/93 were used. Calibration curves of imidazole propionate and urocanate were made in water and treated the same way as the samples.
To measure imidazole propionate in liver, snap-frozen liver samples (50 mg) were extracted with 500 mL of ice-cold acetonitrile containing internal standards (imidazole propionate-13 C 3 and urocanate-13 C 3 , Astra Zeneca, Cambridge, UK) in 1.8 ml polypropylene tube containing ceramic beads. After centrifugation, the supernatant was transferred to a Phree SPE 96-well plate (Phenomenex, Torrance, CA) and eluted onto a collection plate via the positive pressure manifold (Biotage AB, Uppsala, Sweden). After drying the eluate, the samples were reconstituted as described above. After derivatization, the samples were evaporated and reconstituted in 500 ml of water/acetonitrile. Samples (5 ml) were then injected and separated as described above. Mass spectrometric analysis was performed using an Acquity UPLC I-class pump (Waters, Milford, MA) coupled to a Xevo TQ-XS (Waters, Milford, MA). The imidazole propionate and urocanate were detected by multiple reaction monitoring using the transitions 197/81 and 195/93, respectively. For the internal standards, the transitions 200/82 and 198/95 were used. Calibration curves of imidazole propionate and urocanate were made in methanol and treated the same way as the samples.
In vitro gut simulator A simulated human intestinal redox model (SHIRM) was used to directly investigate whether imidazole propionate could be a microbially produced metabolite. SHIRM is a two-chamber fermenter with an anaerobic luminal chamber and an oxygen feeder, which are separated by a CMI-7000S membrane (Membrane International, NJ) and continuously purged with nitrogen and oxygen, respectively. The oxygen chamber contained 100 mM potassium phosphate buffer. The feed for the luminal chamber consisted of (in g/l) arabinogalactan (1.0), pectin (2.0), xylan (1), starch (3.0), glucose (0.4), yeast extract (3.0), peptone (3.0), mucin type II (1.0), NaCl (0.9), KH 2 PO 4 (0.45), K 2 HPO 4 (0.45), CaCl 2 .2H 2 O (0.45), MgSO 4 .7H 2 O (0.09), hemin (0.01) and cysteine (0.5). A vitamin mix [consisting of (in mg/l) biotin (10), cobalamin (10), p-aminobenzoic acid (30), folic acid (50), pyridoxamine (150), riboflavin (50) and thiamine-HCl (50)] was added. To simulate digestion processes, the feed was acidified to a pH of around 2 with 6 M HCl followed by addition of pepsin (10 mg/l) and neutralized with simulated pancreatic juice [(in g/l) NaHCO 3 (12.5), Ox gall bile salts (6.0) and pancreatin (0.9)] to pH 6.9. The luminal chamber was continuously fed with SHIRM feed (70:30 mix of the feed and pancreatic juice described above) at a rate giving a retention time of around 24 h and pH was maintained at 6.6-6.9 using a pH controller and dosing pump (Black Stone BL7916-2, Hanna Instruments, UK).
The SHIRM system was inoculated with aliquots of the feces from subjects with and without type 2 diabetes (from the first cohort); feces from each subject were tested in separate experiments. A pre-culture was prepared anaerobically in a Coy chamber (5% hydrogen, 10% carbon dioxide and 85% nitrogen) by adding 2% fecal material to 5 ml of BHI medium containing (in g/l) yeast extract (5), cellobiose (1), maltose (1), cysteine (0.5) and hemin (0.01). The pre-culture was incubated for 3 h at 37 C, and 2% of the pre-culture was seeded into the luminal compartment of the SHIRM. The luminal communities were stabilized for 1 week before histidine challenge. Samples were collected for up to 7 h and imidazole propionate levels were measured as described above.
Batch culture of fecal samples Fecal samples (100 mg) from donors with and without type 2 diabetes (from both cohorts) were inoculated in 5 ml BHI medium (as described above) and incubated overnight under strict anaerobic conditions in a Coy chamber at 37 C. For the first cohort, we used samples from all five subjects with type 2 diabetes and five subjects without type 2 diabetes selected because they had the lowest concentrations of imidazole propionate and to match for BMI. For the second cohort, we used samples from the three subjects with treatment-naive type 2 diabetes with the highest imidazole propionate concentrations and three subjects with normal glucose tolerance with imidazole propionate levels lower than the median value in this group (7.1 nM); the subjects selected were also sex-and BMI-matched. After incubation, 1% (v/v) of the respective BHI precultures was inoculated in SHIRM feed (described above) supplemented with 10 mM histidine. After 36 h of incubation, supernatants were used for imidazole propionate and urocanate quantification. To adjust for variations in bacterial growth, urocanate levels were measured and levels of produced imidazole propionate were divided by urocanate levels. Fold-change (36 h/0 h) was calculated using these adjusted values.
Computational prediction of UrdA-containing bacteria UrdA was previously predicted to encode fumarate reductase because of its high sequence homology to the FAD-and FMN-binding domains of fumarate reductase, succinate dehydrogenase and L-aspartate oxidase (Bogachev et al., 2012) . However, structural modeling of the FAD-binding domain from UrdA identified differences in amino acid sequences from those in fumarate reductase, which potentially gives substrate selectivity to urocanate (Bogachev et al., 2012) . To screen for potential imidazole propionate-producing bacteria, we focused on amino acid sequences that are conserved in fumarate reductase from Shewanella oneidensis but replaced in potential UrdA. Since conserved ''H''s in the active sites of enzymes are important for catalysis in various enzymes (Schrö der et al., 1991; Wallner et al., 2012; Zhang and Dixon, 1993) , we focused on tyrosine 373 (Y373) in the FAD active sites of UrdA [Y373 corresponds to histidine (H) in fumarate reductase]. Extensive protein screening followed by accurate domain alignment ( Figure S2A ) identified the existence of 812 UrdA homologs in 670 bacterial genomes (Table S4 ). Of those, 639 were identified to have an ''H'' residue in their active sites whereas 173 have non-''H'' residues such as ''Y'' or ''M'' (Table S4 and Figure S2B ).
As shown in Figure S2A , 27 seed protein sequences [including 22 from KEGG annotations (Kanehisa and Goto, 2000) ] with high identity to UrdA from S. oneidensis MR-1 were used to screen potential UrdA homologs among 16,403,888 proteins extracted from 4893 bacterial genomes. These data were downloaded from the NCBI ftp site ftp://ftp.ncbi.nlm.nih.gov/genomes/all/ on June 26, 2016. 658 protein hits were identified using BLASTP program (Camacho et al., 2009 ) (with the following settings: E value = 1e-4; identity = 30%; coverage = 70%) and those hits were further used as seeds to perform both the second round of protein BLAST and HMM profiling (Finn et al., 2011 ) (with at least 50% coverage and score larger than 200), resulting in 2230 and 2526 protein hits, respectively. A further Pfam domain scan (Finn et al., 2016) on all identified UrdA candidates revealed that 1774 sequences possess FAD domains. We thus extracted the FAD active sites of UrdA from S. oneidensis MR-1 (extended to 30 amino acids upstream and downstream of Y373) and performed a third round of protein BLAST against the 1774 FAD-containing hits using the extracted Y373containing domain as the query sequence. 812 protein hits were identified as the final UrdA homologs. Additional domain alignment was performed using ClustalX (Larkin et al., 2007) to annotate the corresponding active sites (Table S4 and Figure S2B ).
Experimental validation of UrdA-containing bacteria
Eight representative UrdA-containing bacterial strains (without conserved ''H'') were further subjected to experimental validation in pure cultures together with Escherichia coli k12 and Bifidobacterium longum NCC2705 as control (with conserved ''H''). The maximum likelihood tree was based on extracted FAD domains from all 10 bacteria using MEGA (version 7) (Kumar et al., 2016) with default settings.
To assess the imidazole propionate-producing potential of pure bacterial cultures, all strains were maintained on BHI medium (as described above) without histidine or urocanate under strict anaerobic conditions in a Coy chamber (5% hydrogen, 10% carbon dioxide and 85% nitrogen) at 37 C. To test their potential to produce imidazole propionate, a single colony of each bacterial strain was inoculated in BHI medium and, after overnight incubation, 1% of the preculture was inoculated in BHI medium supplemented with 10 mM histidine or urocanate and incubated for 24 h. After incubation, the cell-free supernatant was used for quantification of imidazole propionate.
Differential abundance analysis
The metagenomics analysis was based on the MEDUSA pipeline (Karlsson et al., 2014) for mapping and DESeq2 (Love et al., 2014) for differential abundance analysis as described previously (Wu et al., 2017) . 140 out of 143 ''non-H'' ImP-producing bacterial strains (173 at the gene level) (Table S4) with high-quality draft/complete genomes were extracted from NCBI to construct the genome catalog required for the MEDUSA pipeline. All metagenome sequences were retrieved from a previous study (33 subjects with treatment-naive type 2 diabetes and 43 with normal glucose tolerance; Karlsson et al., 2013) with Sequence Read Archive (sra) accession code ERP002469.
Quantitative real-time PCR analysis
Mouse liver was homogenized in RLT buffer with b-mercaptoethanol using TissueLyser. RNA was isolated using the RNeasy Minikit and reverse transcribed to synthesize cDNA using High Capacity cDNA Reverse Transcription Kit according to the manufacturer's protocol. Real-time PCR was performed using 1X SYBR Green Master Mix using the primers in Key Resources Table. Protein analysis Snap-frozen tissues and harvested cells were lysed in buffer A containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 20 mM NaF, 10 mM glycerophosphate, 1 mM PMSF, 10% glycerol, 1% Triton X-100 and protease inhibitor cocktail. For western blotting, the cell lysates were sonicated and centrifuged at 20,000g for 15 min at 4 C, and the supernatant was mixed with 5X Laemmli buffer [0.156 M Tris-HCl (pH 6.8), 25% glycerol, 12.5% b-mercaptoethanol, 12.5% SDS, 0.1% bromophenol blue], followed by heating at 95 C for 10 min. For immunoprecipitation, the cell lysates were obtained in 0.3% CHAPS-containing lysis buffer, sonicated and centrifuged at 20,000g for 15 min at 4 C, and the supernatant was incubated with 20 ml of anti-FLAG beads or 2 mg of the anti-HA antibody at 4 C for 4 h or overnight, respectively, under gentle agitation. Immunocomplexes with anti-HA antibody were collected using protein A-Sepharose beads and were eluted with 2X Laemmli buffer with 100 mM DTT, followed by heating at 95 C for 10 min. Samples treated with Laemmli buffer (20-30 mg for cell lysates or 40-50 mg for tissue lysates to detect basal signal) were separated on Bis-Tris gels or Tris-glycine gels (to detect mTOR), transferred to nitrocellulose membrane, and probed with antibodies indicated. The blots were then reacted with HRP-linked anti-rabbit IgG or anti-mouse IgG, followed by enhanced chemiluminescence.
Plasmids and siRNAs
Myc-Rag GTPases constructs were gifts from Dr. Do-Hyung Kim (University of Minnesota, MN) (Kim et al., 2012) . The GFP-p62 WT construct was kindly provided by Dr. Sung Ouk Kim (University of Western Ontario, London, Ontario, Canada) and the GFP-p62 T269A/S272A mutant was generated by site-directed mutagenesis using a Solg TM Pfu-X DNA polymerase using the primers p62 T269A/S272A F and R (Key Resources Table) . Transfection with plasmids or siRNAs in HEK293 cells was performed using Lipofectamine 2000 according to the manufacturer's instructions.
Immunofluorescence
Cells were grown on poly-L-lysine coated 4 well chamber slides, fixed with 4% paraformaldehyde for 15 min at 37 C, then washed with glycine-PBS and permeablized with 0.3% Triton X-100 for 10 min. After blocking with 3% BSA in PBS, cells were stained for mTOR and LAMP2. Images were obtained by confocal microscope (63X).
In vitro kinase assay 400 ng of recombinant p62 and 200 ng of recombinant p38g were incubated in a kinase assay buffer [25 mM MOPS (pH 7.2), 12.5 mM beta-glycerol-phosphate, 25 mM MgCl 2 , 5 mM EGTA, 2 mM EDTA and 1 mM DTT] for 15 min on ice. In a separate tube, 1 mM ATP diluted in a kinase assay buffer was incubated with DMSO or imidazole propionate (final concentration of ATP in the kinase reaction was 50 or 200 mM). The kinase reaction was started by adding ATP with DMSO or imidazole propionate to the p38g and p62 mixture for 10 min at 30 C, and stopped by adding 5X Laemmli buffer.
Statistical analysis
Wilcoxon rank-sum test was used to test if metabolites in portal blood plasma differed in abundance between subjects with and without type 2 diabetes in the first cohort (untargeted metabolomics); the raw P values were adjusted by the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) with a FDR of 0.1. Kruskal-Wallis rank-sum test followed by Dunnett's multiple comparisons was used for targeted comparisons of imidazole propionate among groups with different levels of glucose tolerance in the second cohort. Multiple regression and analysis of variance with corrections for confounding factors BMI, age and sex were used for this larger cohort. Analysis of datasets containing multiple measurements from mice and humans (comparing metabolites in portal and cava blood plasma) was performed with a two-way ANOVA with repeated-measurements. Wilcoxon one-tailed test was done to see if type 2 diabetes-associated microbiota produces higher imidazole propionate from histidine. One-way ANOVA with Tukey's test was performed when comparing three or more groups. Analysis of effects of imidazole propionate on concentrations of different metabolites or mice physiology (energy expenditure or locomotor activity) depending on light/dark cycle was done with a two-way ANOVA with Sidak's multiple comparisons test. Otherwise, unpaired two-tailed Student's t tests were used, as indicated. 
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